Become A Featured Company

A Different Kind Of Synthetic Cannabis

Ryan Allway

May 22nd, 2017

News

Cannabis has been shown over the decades to be a wonder drug: inflammation reducer, neuroprotectant, and anti-tumor agent are only a few of the titles cannabis holds thanks to diligent research that revealed its remarkable chemical makeup.

Unfortunately, the dark side of cannabis research showed when in the mid to late 2000’s, synthetic cannabinoid analogues flooded the streets as “Spice”: a potpourri incense that was spray treated with synthetic cannabinoids so users could smoke the floral-smelling contents and get a much more intense, cannabis-like high.  Spice and all variants of it were quickly made illegal in the US under a temporary order.  Concern was not without warrant: people as young as early teenagers were being admitted to hospital ER’s as a result of overdosing on these cannabinoid treated products.

Because of this outbreak of deadly cannabinoid designer drugs and the staunchly pro-cannabis majority across the States that refuses all substitutes (Gallup), synthetic cannabinoids quickly became demonized.  But what if not all synthetic cannabinoids were harm inducing to society?  What if there were cannabis-derived compounds created that benefitted mankind?

That day is already here. Based in Boston and Israel, Kalytera, (TSXV: KALY) is a clinical-stage pharmaceutical company that has been developing synthetic cannabinoids with a greater purpose.  Their proprietary synthetic CBD compounds have been engineered with patients in mind.  Focusing currently on the application of CBD’s anti-inflammatory properties, Kalytera has developed six distinct forms of CBD prodrugs, (drugs that help other drugs work better, in layman) that treat a variety of ailments that present with inflammation.

Adult Respiratory Distress Syndrome (ARDS) and K-1012

(ARDS) is a progressive illness that’s linked to triggered inflammation in the lungs.  There is no cure for ARDS and neither is there even an effective therapy for it.  What’s worse is ARDS affects those critically ill or who’ve suffered significant injury.  The main symptom of ARDS is severe shortness of breath, which paired with the stress of illness or injury, often proves fatal.

Kalytera has introduced K-1012, a synthetic cannabinoid for the treatment of ARDS.  While CBD is typically refined from cannabis into an oil form, treatment of ARDS requires medicine to be directly applied to the lungs.  For specific treatment of ARDS, Kalytera has developed an aerosolized medicinal spray that releases CBD much quicker into the lungs than oral administration of CBD oil.  The key difference between organic CBD and this synthetic version, K-1012, is K-1012 is a bi-phosphate derivative of cannabidiol.  This change was made to the compound because of how the fluid in the lungs breaks down phosphates:  Kalytera anticipates the phosphate element of this compound to break down in the fluid of the lungs, dispersing CBD to the lungs quicker and more efficiently.  This process makes CBD deliverable in water whereas it is typically only soluble in oil.

Ulcerative Colitis (UC) and K-1022

(UC) is a chronic medical condition that presents as a result of inflammation of the colonic mucosa, extending from the rectum to the large intestines.  While there are accepted treatments for UC, there are many patients that don’t respond to them.  In these cases, steroids and biologics are used to decrease inflammation.  As steroids are more strenuous on the body than CBD, Kalytera has again developed a variant synthetic that’s designed to specifically hone in on the organs that UC affects.

K-1022 is an orally administered cannabinoid derivative that was designed as a bi-sulfate.  Because there are sulfatases specifically in the colon, the bi-sulfate formula is expected to increase the efficiency of CBD reaching the colon before being processed by other systems during digestion.

Acne and K-1032

As reported, 80% of adolescents develop acne during puberty.  Acne Vulgaris, or just “acne”, is a result of activation of inflammation in the pilosebaceous unit.  Though acne is not life threatening, it is a persistent condition for some, despite rigorous treatments that often have side effects.  There are also many treatments currently available, however there is still a serious need for a well-tolerated treatment for acne that is as safe as it is effective.

K-1032 is a revolutionary synthetic cannabinoid that can be paired with traditional acne treatments in order to decrease inflammation and control acne breakouts while also reducing possible inflammation from concentrated acne creams.  K-1032 has been developed in several formulations but all of them can be applied topically to affected areas of acne.

Acute Renal Failure (ARF) and Traumatic Brain Injury (TBI) and K-1052

(ARF) is an extremely common complication patients suffer after becoming critically ill.  It affects more than 35% of critically ill patients and regardless of advances in treatment, it is still claiming over 50% of patients that suffer from it who are admitted to the Intensive Care Unit.  In all cases of ARF, there is an inflammatory response because of the kidney failure.

(TBI) is vaguely similar to ARF, because similarly to how the renal failure sets off a chain reaction of inflammatory processes around the organ, the brain also suffers from inflammation and chain reaction injuries as a result of it.

Pioneering a combination of two active ingredients, Kalytera has developed K-1052, which fuses CBD and (S)-2-amino-(1-iminoethylamino)-5-thioheptanoic acid.  As has been established, CBD acts as an anti-inflammatory while the other active ingredient inhibits the release of chemicals in the brain or kidney that begin the chain reaction causing organ shut down.  This synthetic cannabinoid, K-1052 has already been tested in Phase III human trials and further safety and toxicology trials are slated for the drug.  Sufferers of ARF often have no other choice but renal replacement therapy.  There is no current treatment for ARF.  Similarly, there is no curative treatment for the cascading failure effect within the brain after a TBI.

Bone Fracture and KAL436 / KAL 671

In the US alone, there are over 10 million estimated hospital and doctor visits as a result of bone fractures.  Most commonly, osteoporosis is the cause for bone fractures, and the increasing age of the populous has experts agreeing that incidents of osteoporosis and bone fracture will rise in coming years.

Newly touting KAL436 and KAL671, Kalytera has modified the CBD structure to greatly increase water solubility.  In KAL671 specifically, they took this water soluble cannabinoid and mixed it with a synthetic fatty acid amide which should assist in bone restoration in folks suffering from osteoporosis.  The market for drugs to treat osteoporosis is expected to hit $8.9 billion by 2020.

In Conclusion

While medical cannabis practitioners vehemently argue that whole plant cannabis is the best treatment for any ailment, it is clear that for some conditions, synthetic cannabinoids may be better at selectively targeting organs and systems than CBD itself.  Minor tweaks to chemical composition literally mean the development of a medicine that can revive someone from kidney shut down.

Although organic cannabis is an effective treatment for many conditions, don’t blindly believe in the demonization of synthetic cannabinoids.  It wasn’t long ago that the “dangers” of Mexican “marijuana” were enough to sway citizens to make the plant illegal; not realizing that they’d just made their victory hemp crops illegal, too.  Synthetic cannabinoids are not all created equal. As long as our fear doesn’t block us from it, they could be the next wave of life-saving medications.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading